Relationship between extent of inhibition and inhibitor dose: Literature evaluation based on the metabolism and transport drug interaction database

Current Drug Metabolism

Volumn 4, Issue 5, 2003, Pages 371-380

  Levy, R H ^a   Hachad, H ^a   Yao, C ^b   Ragueneau Majlessi, I ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cytochrome P450; Database; Dose dependent inhibition; Drug interaction; In vivo inhibition constant; Mechanism based inhibition; Reversible inhibition

Indexed keywords

AMPRENAVIR; CAFFEINE; CIMETIDINE; CIPROFLOXACIN; CYTOCHROME P450; DILTIAZEM; DISULFIRAM; ENOXACIN; FELBAMATE; FLUCONAZOLE; FLUVOXAMINE; INDINAVIR; KETOCONAZOLE; MEPHENYTOIN; NIFEDIPINE; NORTRIPTYLINE; OMEPRAZOLE; PAROXETINE; PHENYTOIN; QUINIDINE; RITONAVIR; TACRINE; TACROLIMUS; THEOPHYLLINE; TOLBUTAMIDE; TRIAZOLAM; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; WARFARIN;

AREA UNDER THE CURVE; BIBLIOGRAPHIC DATABASE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INFORMATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TRANSPORT; EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; INTERNET; MEDICAL LITERATURE; METHODOLOGY; REVIEW;

ANIMALS; ANTIMETABOLITES; BIOLOGICAL TRANSPORT; DATABASES, FACTUAL; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0142042804     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389200033489325     Document Type: Review

References (40)

1. Kunze, K.L.; Wienkers, L.C.; Thummel, K.E. and Trager, W.F. (1996) Drug Metab. Dispos., 24(4), 414-21.
2. Kunze, K.L. and Trager, W.F. (1996) Drug Metab. Dispos., 24(4), 429-35.
3. Yao, C.; Kunze, K.L.; Kharasch, E.D.; Wang, Y.; Trager, W.F.; Ragueneau, I. and Levy, R.H. (2001) Clin. Pharmacol. Ther., 70, 415-424.
4. Yao, C.; Kunze, K.L.; Trager, W.F.; Kharasch, E.D. and Levy, R.H. (2003) Drug Metab. Dispos., 31(5), 565-71.
5. Neal, J.M.; Kunze, K.L.; Levy, R.H.; O'Reilly, R.A. and Trager, W.F. (2003) Drug Metab. Dispos., 31(8), 1043-1048.
6. Mayhew, B.S.; Jones, D.R. and Hall, S.D. (2000) Drug Metab. Dispos., 28(9), 1031-7.
7. Jones, D.R. and Hall, S.D. (2002) in Drug-Drug Interactions (Rodrigues, A.D.), Marcel Dekker Inc., New York, Basel, pp 387-413.
8. Metabolism and Transport Drug Interaction Database. http://depts.washington.edu/didbase. Accessed: August 2003. Copyright University of Washington 1999-2003.
9. Carlson, S.P.; Ragueneau-Majlessi, I. and Levy, R.H. (2002) in Drug-Drug Interactions (Rodrigues, A.D.), Marcel Dekker Inc., New York, Basel, pp 549-563.
10. Back, D.J.; Tjia, J.; Monig, H.; Ohnhaus, E.E. and Park, B.K. (1988) Eur. J. Clin. Pharmacol., 34(2),157-63.
11. Sax, M.J.; Randolph, W.C.; Peace, K.E.; Chretien, S.; Frank, W.O.; Braverman, A.J.; Gray, D.R.; McCree, L.C.; Wyle, F. and Jackson, B.J. (1987) Clin. Pharm., 6(6),492-5.
12. Harder, S.; Staib, A.H.; Beer, C.; Papenburg, A.; Stille, W. and Shah, P.M. (1988) Eur. J. Clin. Pharmacol., 35(6), 651-6.
13. Tateishi, T.; Ohashi, K.; Sudo, T.; Sakamoto, K.; Toyosaki, N.; Hosoda, S.; Toyo-oka, T.; Kumagai, Y.; Sugimoto, K. and Fujimura, A. (1989) J. Clin. Pharmacol., 29(11), 994-7.
14. Jones, T.E. and Morris, R.G. (2002) Clin. Pharmacokinet., 41(5), 381-8.
15. Beach, C.A.; Mays, D.C.; Guiler, R.C.; Jacober, C.H. and Gerber, N. (1986) Clin. Pharmacol. Ther., 39(3), 265-70.
16. Loi, C.M.; Day, J.D.; Jue, S.G.; Bush, E.D.; Costello, P.; Dewey, L.V. and Vestal, R.E. (1989) Clin. Pharmacol. Ther., 45(5), 476-86.
17. Rogge, M.C.; Solomon, W.R.; Sedman, A.J.; Welling, P.G.; Toothaker, R.D. and Wagner, J.G. (1988) Clin. Pharmacol. Ther., 44(5), 579-87.
18. Wilensky, A.J.; Friel, P.N.; Ojemann, L.M.; Kupferberg, H.J. and Levy, R.H. (1985) Epilepsia, 26(6), 602-6.
19. Sachdeo, R.; Wagner, M.L.; Sachdeo, S.; Shumaker, R.C.; Lyness, W.H.; Rosenberg, A.; Ward, D.; Perhach, J.L. (1999) Epilepsia, 40(8), 1122-8.
20. Tran, A.; Rey, E.; Pons, G.; Rousseau, M.; d'Athis, P.; Olive, G.; Mather, G.G.; Bishop, F.E.; Wurden, C.J.; Labroo, R.; Trager, W.; Kunze, K.L.; Thummel, K.E.; Vincent, J.C.; Gillardin, J.M.; Lepage, F. and Levy, R.H. (1997) Clin. Pharmacol. Ther., 62(5), 490-504.
21. Hooper, W.D.; Franklin, M.E.; Glue, P.; Banfield, C.R.; Radwanski, E.; McLaughlin, D.B.; McIntyre, M.E.; Dickinson, R.G. and Eadie, M.J. (1996) Epilepsia, 37(1), 91-7.
22. Varhe, A.; Olkkola, K.T. and Neuvonen, P.J. (1996) Br. J. Clin. Pharmacol., 42(4), 465-70.
23. Christensen, M.; Tybring, G.; Mihara, K.; Yasui-Furokori, N.; Carrillo, J.A.; Ramos, S.I.; Andersson, K.; Dahl, M.L.; Bertilsson, L. (2002) Clin. Pharmacol. Ther., 71(3), 141-52.
24. Larson, J.T.; Hansen, L.L.; Spigset, O. and Brosen, K. (1999) Eur. J. Clin. Pharmacol., 55(5), 375-82.
25. Madsen, H.; Enggaard, T.P.; Hansen, L.L.; Klitgaard, N.A. and Brosen, K. (2001) Clin. Pharmacol. Ther., 69(1), 41-7.
26. Bottiger, Y.; Tybring, G.; Gotharson, E. and Bertilsson, L. (1997) Clin. Pharmacol. Ther., 62(4), 384-91.
27. Laine, K.; Tybring, G.; Hartter, S.; Andersson, K.; Svensson, J.O.; Widen, J. and Bertilsson, L. (2001) Clin. Pharmacol. Ther., 70(4), 327-35.
28. Edwards, D.J.; Lavoie, R.; Beckman, H.; Blevins, R. and Rubenfire, M. (1987) Clin. Pharmacol. Ther., 41(1), 68-73.
29. Stringer, K.A.; Mallet, J.; Clarke, M. and Lindenfeld, J.A. (1992) Eur. J. Clin. Pharmacol., 43(1), 35-8.
30. Sadler, B.M.; Piliero, P.J.; Preston. S.L.; Lloyd, P.P.; Lou, Y. and Stein, D. S. (2001) AIDS, 15(8), 1009-18.
31. Hsu, A.; Granneman, G.R.; Cao, G.; Carothers, L.; Japour, A.; El-Shourbagy, T.; Dennis, S.; Berg, J.; Erdman, K.; Leonard, J.M. and Sun, E. (1998) Antimicrob. Agents Chemother., 42(11), 2784-91.
32. Kurowski, M.; Kaeser, B.; Sawyer, A.; Popescu, M. and Mrozikiewicz, A. (2002) Clin. Pharmacol. Ther., 72(2),123-32.
33. Buss, N.; Snell, P.; Bock, J.; Hsu, A. and Jorga, K. (2001) Br. J. Clin. Pharmacol., 52(3), 255-64.
34. Spigset, O.; Granberg, K.; Hagg, S.; Soderstrom, E. and Dahlqvist, R. (1998) Br. J. Clin. Pharmacol., 45(3), 257-263.
35. http://www.fda.gov/cder/guidance/; Accessed in August 2003. In vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis and Recommendations for Dosing and Labeling (1999).
36. Bjornsson, T.D.; Callaghan, J.T.; Einolf, H.J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S.P.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, S.R.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J.T.; Tweedie, D.; Vega, J.M.; Walsh, J. and Wrighton, S.A. (2003) J. Clin. Pharmacol., 43(5), 443-69.
37. Thummel, K.E.; Kunze, K.L. and Shen, D.D. (2000) in Metabolic Drug Interactions (Levy, R.H.; Thummel, K.E.; Trager, W.F.; 6Hansten, P.D. and Eichelbaum, M.), Lippincott-Raven Publishers, Philadelphia, pp. 3-19.
38. Lin, J.H. (2000) Curr. Drug Metab., 1(4), 305-331.
39. Rowland, M. and Matin, S.B. (1973). J. Pharmacokinet. Biopharm., 1, 553-567.
40. Shaw, P.N. and Houston, J.B. (1987) J. Pharmacokinet. Biopharm. 15(5), 497-510.